Strategic Focus AB Science specializes in targeted therapies using tyrosine kinase inhibitors for high-need areas such as oncology, chronic inflammatory diseases, and neurological degenerative disorders, presenting multiple cross-sell opportunities across hospitals and specialist physicians.

Clinical Momentum With ongoing phase 2 and phase 3 trials in oncology and non-oncology diseases, AB Science offers opportunities for investigator-initiated studies, clinical collaborations, and sponsorships to accelerate access and data generation.

Pipeline Readiness A robust drug discovery platform plus several preclinical candidates provide downstream opportunities for partnership in research collaborations, licensing discussions, and early-stage out-licensing to biopharma or CROs specializing in late-stage development.

Geographic Reach Lead compound masitinib is already in veterinary commercialisation and human medicine trials, enabling cross-market selling motions to veterinary clinics, hospitals, and specialty centers, as well as potential regional co-promotion deals.

Strategic Partnerships Past collaborations such as the University of Chicago and ongoing high-profile conference presentations create pathways for co-development, grant funding opportunities, and exposure to potential strategic investors or licensing partners.